Role of increased circulating and renal adrenomedullin in rats with malignant hypertension.
Although it has been reported that the circulating adrenomedullin (AM) level is elevated in hypertension and renal failure, the pathophysiological significance of circulating and intrarenal AM in malignant hypertension remains unknown. We investigated the circulating and intrarenal AM system in rats with malignant hypertension by measuring the plasma level, renal tissue level, and mRNA abundance of AM and the mRNA abundance of AM receptor. We also investigated the effects of intravenously infused calcitonin gene-related peptide (CGRP)-(8-37), an antagonist of AM, on the hemodynamics and renal tubular function. We studied the following four groups: control Wistar-Kyoto rats (WKY), control spontaneously hypertensive rats (C-SHR), salt-loaded SHR (S-SHR), and DOCA-salt SHR (D-SHR). After 3 wk of DOCA treatment, D-SHR developed malignant hypertension. D-SHR were characterized by higher blood pressure, kidney weight, urinary protein excretion and blood urea nitrogen, and lower creatinine clearance compared with the other three groups. The plasma AM level and urinary excretion of AM were markedly higher in D-SHR than in the other three groups. In the kidney, the tissue AM level and the expression of AM mRNA in the renal medulla were significantly increased in D-SHR compared with the other three groups, whereas there were no significant differences in these levels in the renal cortex among the four groups. In the renal AM receptor system, the expression of the gene for receptor activity modifying protein 3 was significantly increased in the renal medulla in D-SHR compared with the other three groups. An immunohistochemical study revealed that AM immunostaining in renal collecting duct cells and distal tubules was more intense in D-SHR than in the other three groups. After CGRP-(8-37) infusion, blood pressure increased significantly and urinary sodium excretion and urine flow decreased significantly only in D-SHR. These results suggest that the increased circulating AM and renal AM and the increased expression of the mRNA for AM and its receptor may at least partly compensate for the malignant hypertensive state in certain forms of malignant hypertension via the hypotensive, natriuretic, and diuretic actions of AM.
Nishikimi
T
T
Research Institute, Fujishirodai, Suita, Osaka 565, Japan. nishikim@dokkyomed.ac.jp
Yoshihara
F
F
Kanazawa
A
A
Okano
I
I
Horio
T
T
Nagaya
N
N
Yutani
C
C
Matsuo
H
H
Matsuoka
H
H
Kangawa
K
K
D053607:Adrenomedullin; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D015152:Blotting, Northern; D001835:Body Weight; D058286:Calcitonin Receptor-Like Protein; D003404:Creatinine / Q000378:metabolism; D003900:Desoxycorticosterone / Q000494:pharmacology; D004231:Diuresis / Q000187:drug effects; D006321:Heart / Q000033:anatomy & histology / Q000187:drug effects; D006339:Heart Rate / Q000187:drug effects; D006974:Hypertension, Malignant / Q000097:blood* / Q000503:physiopathology; D047908:Intracellular Signaling Peptides and Proteins; D007668:Kidney / Q000503:physiopathology*; D008297:Male; D008565:Membrane Proteins / Q000235:genetics; D009929:Organ Size; D010455:Peptides / Q000097:blood / Q000378:metabolism*; D011507:Proteinuria; D051381:Rats; D011918:Rats, Inbred SHR; D011921:Rats, Inbred WKY; D058261:Receptor Activity-Modifying Proteins; D018003:Receptors, Calcitonin / Q000235:genetics; D014158:Transcription, Genetic; D014508:Urea / Q000378:metabolism
D058286:Calcitonin Receptor-Like Protein; D047908:Intracellular Signaling Peptides and Proteins; D008565:Membrane Proteins; D010455:Peptides; D058261:Receptor Activity-Modifying Proteins; D018003:Receptors, Calcitonin; D053607:Adrenomedullin; D003900:Desoxycorticosterone; D014508:Urea; D003404:Creatinine